Centre for Drug Design & Discovery (CD3)
VC Fund
Leuven, Belgium
Centre for Drug Design & Discovery (CD3) is a VC fund in Leuven focused on Therapeutics and Biotechnology. The Centre for Drug Design and Discovery (CD3) is an investment fund and technology transfer platform aimed at promoting the discovery and development of innovative medicines for all kinds of diseases. CD3 achieves this goal by building further on the enormous pool of basic knowledge, innovation and technology of universities and spin-offcompanies. By providing the necessary expertise and financial resources, CD3 ensures that fundamental biomedical research carried out by universities and small biotech companies is translated into more usable results and promising molecules for new medicines. These new, potential medicines can then be further developed by pharmaceutical companies or form the basis for new spin-off companies. With this work method and philosophy, CD3 bridges the gap between academic innovative research and the pharmaceutical industry.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Centre for Drug Design & Discovery (CD3) invests in
Stages Centre for Drug Design & Discovery (CD3) invests in
Countries Centre for Drug Design & Discovery (CD3) invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Arnaud Marchand
|
|||
|
Patrick Chaltin
|
|||
Stefaan Allemeersch
|
|||
Investment Focus
Industry
- Therapeutics 2 (67%)
- Biotechnology 2 (67%)
- Health Care 1 (33%)
Stage
- Seed 1 (33%)
- Series A 1 (33%)
- Series B 1 (33%)
Country
- Belgium 1 (33%)
- United States 1 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Arnaud Marchand
Executive Director Medicinal Chemistry
|
Executive Director Medicinal Chemistry | Total investments: 0 | Find email | |
|
Patrick Chaltin
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
|
Stefaan Allemeersch
Executive Director Business Development
|
Executive Director Business Development | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Endlyz Therapeutics
|
ndLyz Therapeutics, Inc. is developing disease-modifying therapeutics which restore endo-lysosomal function and abrogate neurodegeneration in Parkinson’s disease (PD) and other dementias. | $17.3M / Seed / Apr 23, 2026 | |
Rewind Therapeutics
|
Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy. | Series B / Jan 25, 2023 | |
|
Rewind Therapeutics
|
Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy. | Series A / Jan 25, 2023 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Centre for Drug Design & Discovery (CD3) invest in?
Centre for Drug Design & Discovery (CD3) invests primarily in Therapeutics, Biotechnology and Health Care startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Centre for Drug Design & Discovery (CD3)?
Public channels for Centre for Drug Design & Discovery (CD3) include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Centre for Drug Design & Discovery (CD3)?
The team at Centre for Drug Design & Discovery (CD3) includes Arnaud Marchand (Executive Director Medicinal Chemistry), Patrick Chaltin (Managing Director) and Stefaan Allemeersch (Executive Director Business Development). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
